Gujarat Kidney & Super Speciality Ltd FY26: Doubling Down on Acquisitions, Not Earnings

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1 — At a Glance

Revenue hit ₹82 crore in FY26, up 104% year-on-year. The consolidated picture is sharper: ₹82 crore (parent) swells to ₹820 crore (consolidated), a six-fold jump that lives almost entirely in the acquisition column.

Net profit landed at ₹15.5 crore (parent), up 65% YoY. On a consolidated basis, ₹16.8 crore. The multiple has widened—the stock trades at 63x earnings. That number sits bang in the peer median for healthcare operators (peer median P/E: 45.8x), so the market isn’t screaming “overvalued,” but it isn’t bargaining either.

The balance sheet has bulked up: cash rose from ₹2.8 crore to ₹56.3 crore by June 2025. Yet receivables now sit at 172 debtor days—hospitals don’t ship goods, so the real test is whether that cash translates into bed utilization and margin expansion, not just sitting there as a war chest.

The company closed three acquisitions in the first quarter of FY26 (Ashwini, Harmony Medicare, Patel entities) and a fourth—Parekhs Hospital in Ahmedabad for ₹77 crore—in March 2026. The tension: rapid inorganic growth can scale capacity, but it also masks whether the core business is improving or just getting bigger.

2 — Introduction

Gujarat Kidney & Super Speciality Limited is a five-year-old regional healthcare operator anchored in central Gujarat, born in 2019. It went public in December 2025 via IPO, raising ₹251 crore in fresh capital.

The company operates under an acquisition strategy—buy controlling stakes in operational hospitals, integrate them, and move on. Think of it as a mini-roll-up play in a fragmented regional healthcare market. The core holding is Gujarat Kidney & Superspeciality Hospital in Vadodara, a 180-bed multi-specialty facility focused on renal sciences (urology, nephrology, transplants) but broadened into cardiology, oncology, orthopaedics, and laparoscopy.

By March 2026, the consolidated portfolio stretched across five cities: Vadodara, Bharuch, Godhra, Anand, and Borsad. Total 539 beds on paper; 389 operational, 80 ICU. The parent company, GKSL, holds 100% of Parekhs Hospital (Ahmedabad, 49 beds) and Ashwini Medical Centre (Anand), and 49% of Harmony Medicare and 51% of Patel entities. This mix is then consolidated into one P&L.

The IPO banner promised capex for robotics, acquisition part-payments, and debt repayment. In the March Board meeting, management deferred the CEO appointment and moved to a postal ballot to reallocate IPO proceeds—a red flag that the original plan has shifted, though not formally disclosed.

3 — Business Model: WTF Do They Even Do?

GKSL is not running a single hospital; it is running a network of acquired hospitals with variable operational maturity.

The Core: Gujarat Kidney & Superspeciality in Vadodara, built circa 2019, is the founder’s pride—renal and cardiology focus, decent occupancy, recognized brand in the region. ARPOB (average revenue per occupied bed) ₹10,255 per day, bed occupancy ~56%, ALOS (average length of stay) ~6 days. In a 180-bed facility, those numbers imply steady medium-term demand from insured patients and self-pay, with a chunk from Ayushman Bharat schemes (9.7% of revenue mix).

Revenue Mix: self-pay and others (68.8%), insurance/TPA (21%), government schemes (9.7%). This is healthcare’s bread-and-butter: insured patients with decent length-of-stay cases (nephrology transplants, cardiac interventions) pay better than outpatient foot-traffic.

The Acquisition Play: Parekhs Hospital (Ahmedabad, 49 beds, bought March 2026 for ₹77 crore) is the flagship acquisition. Ashwini in Anand, Harmony Medicare in another pocket, Patel entities in yet another. The model is simple: buy a working hospital, plug it into GKSL’s procurement and referral systems, extract cost synergies, and leave the local doctors and staff in place. No greenfield building, no capex risk on empty beds. Leverage the parent’s scale for supplies, IT, billing.

The risk is equally simple: if bed occupancy doesn’t rise post-acquisition, or if local teams resist consolidation, the acquired hospital becomes a cash sink. At 56% average occupancy across the network, there’s room to grow. But adding 49 beds at Parekhs (₹77 crore cost) assumes those beds will fill—or at least fill faster than the Vadodara core.

The Technology Halo: The May 2026 announcement of 100 AI-powered haemodialysis machines (8 going live at Godhra within 10 days) signals a nod to the premium-service story. AI dialysis machines cost more, attract patients willing to pay, and differentiate a regional operator from the teaching-hospital cartel. But rolling out 100 machines across a 389-bed operational network (net of excess capacity) is a bet that demand will materialize and insurance will reimburse. A symbolic move, not a strategic game-changer yet.

4 — Financials Overview

Figures are consolidated, in ₹ crore.

Latest Year: FY26 (Year Ended Mar 2026)

Quarterly Trajectory (Q4 FY26 vs Q3)

The final quarter saw revenue jump to ₹30.58 crore from ₹23.25 crore in Dec 2025 quarter. Expenses rose sharply (₹24.28 crore from ₹16.35 crore), but operating profit held at ₹6.30 crore. The margin compressed: Q4 OPM 20.6% vs Q3 29.7%, a signal that either integrating the March acquisitions dragged margins or one-time costs hit hard.

PAT for Q4 turned positive at ₹5.04 crore but at a narrower margin than prior quarters. Interest expense rose to ₹0.82 crore in Q4 from ₹0.60 crore in Q3—borrowings increased as the company funded the Parekhs deal.

5 — Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.

The market pays 63x earnings for GKSL versus a peer median of 45.8x. At face value, the stock appears to trade at a 38% premium to peers. But the peer set (Apollo, Max, Fortis, Aster, Narayana, Global Health, Krishna Institute) are large, multi-city operators with scale, brand, and stable cash flows. GKSL is six months old as a public entity and three weeks into integrating a ₹77-crore acquisition. The premium likely prices in IPO flow and acquisition optionality, not superior earnings power today.

Return on Equity sits at 11.1%—below the peer median of 13.2% and weak relative to cost of capital. The company is generating ₹11 of profit for every ₹100 of shareholder equity. ROCE (14.5%) mirrors the peer average (14.7%) and hints that the capital tied up in the hospital network is not yet earning a high return. When the company writes down an asset or integrates a new acquisition, these ratios will jitter. For a newly public operator, 11-15% returns are not damning, but they’re not compelling either.

The market appears to be